MX2023002997A - Metodo de tratamiento de la amiloidosis. - Google Patents
Metodo de tratamiento de la amiloidosis.Info
- Publication number
- MX2023002997A MX2023002997A MX2023002997A MX2023002997A MX2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A MX 2023002997 A MX2023002997 A MX 2023002997A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- treating
- disorder
- methods
- amyloidosis disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078258P | 2020-09-14 | 2020-09-14 | |
| US202063116100P | 2020-11-19 | 2020-11-19 | |
| US202163176015P | 2021-04-16 | 2021-04-16 | |
| PCT/US2021/050316 WO2022056484A1 (en) | 2020-09-14 | 2021-09-14 | Method of treating amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002997A true MX2023002997A (es) | 2023-05-11 |
Family
ID=80631942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002997A MX2023002997A (es) | 2020-09-14 | 2021-09-14 | Metodo de tratamiento de la amiloidosis. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230364228A1 (https=) |
| EP (1) | EP4210753A4 (https=) |
| JP (1) | JP2023541191A (https=) |
| KR (1) | KR20230069161A (https=) |
| AU (1) | AU2021339851A1 (https=) |
| CA (1) | CA3192069A1 (https=) |
| IL (1) | IL301047A (https=) |
| MX (1) | MX2023002997A (https=) |
| WO (1) | WO2022056484A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240055101A (ko) * | 2021-09-14 | 2024-04-26 | 시일럼 바이오사이언시즈, 인크. | 다발성 골수종의 치료 방법 |
| KR20250075597A (ko) * | 2022-09-16 | 2025-05-28 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 심장 아밀로이드증의 치료를 위한 bag3 방법 및 용도 |
| WO2025194030A1 (en) | 2024-03-15 | 2025-09-18 | Alexion Pharmaceuticals, Inc. | Treatment of mayo stage iiib light chain amyloidosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005299716B2 (en) * | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| US20090028847A1 (en) * | 2007-04-12 | 2009-01-29 | Trustees Of Boston University | Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| EP4582446A3 (en) * | 2019-03-05 | 2025-08-13 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
-
2021
- 2021-09-14 CA CA3192069A patent/CA3192069A1/en active Pending
- 2021-09-14 KR KR1020237012401A patent/KR20230069161A/ko active Pending
- 2021-09-14 US US18/026,185 patent/US20230364228A1/en active Pending
- 2021-09-14 WO PCT/US2021/050316 patent/WO2022056484A1/en not_active Ceased
- 2021-09-14 AU AU2021339851A patent/AU2021339851A1/en active Pending
- 2021-09-14 MX MX2023002997A patent/MX2023002997A/es unknown
- 2021-09-14 JP JP2023516809A patent/JP2023541191A/ja active Pending
- 2021-09-14 IL IL301047A patent/IL301047A/en unknown
- 2021-09-14 EP EP21867833.2A patent/EP4210753A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4210753A4 (en) | 2025-01-08 |
| AU2021339851A1 (en) | 2023-04-13 |
| US20230364228A1 (en) | 2023-11-16 |
| IL301047A (en) | 2023-05-01 |
| KR20230069161A (ko) | 2023-05-18 |
| EP4210753A1 (en) | 2023-07-19 |
| WO2022056484A1 (en) | 2022-03-17 |
| AU2021339851A8 (en) | 2023-04-20 |
| JP2023541191A (ja) | 2023-09-28 |
| CA3192069A1 (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002997A (es) | Metodo de tratamiento de la amiloidosis. | |
| JOP20230124A1 (ar) | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها | |
| MY202279A (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| MY199903A (en) | Combination therapy with controlled-release cnp agonists | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| BR112021018262A2 (pt) | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| BR112022015151A2 (pt) | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| EP4484952A3 (en) | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| Novello et al. | Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| MX2024004514A (es) | Terapia de combinacion con el inhibidor de o-glcnacasa (oga). | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| MX2025000682A (es) | Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma | |
| PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| BR112022025901A2 (pt) | Composições e métodos para tratar transtorno obsessivo-compulsivo |